<DOC>
	<DOCNO>NCT02979431</DOCNO>
	<brief_summary>The primary objective evaluate anti-viral effect safety different dos inhale ALX-0171 subject hospitalize Respiratory Syncytial Virus Lower Respiratory Tract Infection ( RSV LRTI ) . The secondary objective evaluate clinical activity , pharmacokinetic ( PK ) property , pharmacodynamic ( PD ) effect immunogenicity different dos inhale ALX-0171 .</brief_summary>
	<brief_title>Dose Ranging Study ALX-0171 Infants Hospitalized Respiratory Syncytial Virus Lower Respiratory Tract Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<criteria>Subject otherwise healthy , hospitalize clinically diagnose RSV LRTI Subject positive RSV diagnostic test . Symptoms likely related RSV infection appear within 4 day screen yet improve screen . Others define protocol Subject know significant comorbidities Subject know human immunodeficiency virus ( HIV ) positive Subject known immunocompromised Subject suspect active , clinically relevant concurrent infection Others define protocol</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>2 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>